The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity

Journal of Mammary Gland Biology and Neoplasia

Volumn 17, Issue 1, 2012, Pages 65-77

  Howe, Erin N ^a,b   Cochrane, Dawn R ^b   Richer, Jennifer K ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; EMT; MET; miR 200; miR 221; miR 222

Indexed keywords

MICRORNA; MICRORNA 200; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG;

ANOIKIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL POLARITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; MULTIGENE FAMILY; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR DIFFERENTIATION;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICRORNAS;

EID: 84858703841     PISSN: 10833021     EISSN: 15737039     Source Type: Journal    
DOI: 10.1007/s10911-012-9244-6     Document Type: Review

References (142)

1. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17(3):118-26. (Pubitemid 46357525)
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-33.
3. Williams AE, Moschos SA, Perry MM, Barnes PJ, Lindsay MA. Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. Developmental Dynamics: An Official Publication of the American Association of Anatomists. 2007;236(2):572-80. (Pubitemid 46233301)
4. Blakaj A, Lin H. Piecing together the mosaic of early mammalian development through microRNAs. J Biol Chem. 2008;283 (15):9505-8.
5. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9(3):219-30. (Pubitemid 351301826)
6. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15 (2):117-34.
7. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548-58. (Pubitemid 41267170)
8. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-54.
9. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-42. (Pubitemid 43278296)
10. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818-29. (Pubitemid 351757205)
11. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-28. (Pubitemid 46809165)
12. Remacle JE, Kraft H, LerchnerW,Wuytens G, Collart C, Verschueren K, et al. New mode of DNA binding of multi-zinc finger transcription factors: deltaEF1 family members bind with two hands to two target sites. EMBO J. 1999;18(18):5073-84. (Pubitemid 29443809)
13. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem. 2002;277(42):39209-16. (Pubitemid 35190890)
14. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005;24(14):2375-85. (Pubitemid 40546696)
15. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007;26(49):6979-88. (Pubitemid 350014612)
16. Shirakihara T, Saitoh M, Miyazono K. Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell. 2007;18(9):3533-44. (Pubitemid 47378691)
17. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007;67(17):7972-6. (Pubitemid 47395127)
18. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593-601. (Pubitemid 351627379)
19. Park S-M, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22 (7):894-907. (Pubitemid 351482843)
20. Stinson S, Lackner MR, Adai AT, Yu N, Kim H-J, O'Brien C, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-tomesenchymal transition in breast cancer. Sci Signal. 2011;4(177): ra41.
21. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 2010;1 (6):306-19.
22. Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y, Burmester S, et al. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 2010;29(30):4297-306.
23. Hurteau GJ, Carlson JA, Roos E, Brock GJ. Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle. 2009;8(13):2064-9.
24. Kenney PA, Wszolek MF, Rieger-Christ KM, Neto BS, Gould JJ, Harty NJ, et al. Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 2011;107(4):656-63.
25. Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci. 2010;55 (8):2365-72.
26. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11(12):1487-95.
27. Yang Y, Ahn Y-H, Gibbons DL, Zang Y, Lin W, Thilaganathan N, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011;121(4):1373-85.
28. Wang Z, Zhao Y, Smith E, Goodall GJ, Drew PA, Brabletz T, et al. Reversal and prevention of arsenic-induced human bronchial epithelial cell malignant transformation by microRNA-200b. Toxicol Sci. 2011;121(1):110-22.
29. Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med. 2010;14(1-2):206-14.
30. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010;8(9):1207-16.
31. Sossey-Alaoui K, Bialkowska K, Plow EF. The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem. 2009;284(48):33019-29.
32. Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011;13(2):R45.
33. Xia W, Li J, Chen L, Huang B, Li S, Yang G, et al. MicroRNA- 200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells. Mol Cell Biochem. 2010;344(1-2):261-6.
34. Hyun S, Lee JH, Jin H, Nam J, Namkoong B, Lee G, et al. Conserved MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K. Cell. 2009;139(6):1096-108.
35. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034-9.
36. Geiger TR, Peeper DS. Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res. 2007;67(13):6221-9. (Pubitemid 47037503)
37. Cameron HL, Foster WG. Dieldrin promotes resistance to anoikis in breast cancer cells in vitro. Reprod Toxicol. 2008;25(2):256-62.
38. Smit MA, Geiger TR, Song J-Y, Gitelman I, Peeper DS. A Twist- Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol. 2009;29(13):3722-37.
39. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009;8(5):1055-66.
40. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR- 200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010;2010:821717.
41. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res. 2005;11(1):298-305. (Pubitemid 40075808)
42. Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol. 2008;27(2):207-12.
43. Stengel C, Newman SP, Leese MP, Potter BVL, Reed MJ, Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2010;102(2):316-24.
44. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer. 2007;120(10):2078-85. (Pubitemid 46555844)
45. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16 Suppl 4:iv14-19. (Pubitemid 43084940)
46. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194-204.
47. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127(8):1785-94.
48. Chen J, Tian W, Cai H, He H, Deng Y. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Medical Oncology (Northwood, London, England) [Internet]. 2011 Nov 19 [cited 2011 Dec 12];Available from: http:// www.ncbi.nlm.nih.gov/pubmed/22101791.
49. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15 (16):5060-72.
50. Schickel R, Park S-M, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010;38(6):908-15.
51. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8. (Pubitemid 40839735)
52. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66. (Pubitemid 44629897)
53. Grelier G, Voirin N, Ay A-S, Cox DG, Chabaud S, Treilleux I, et al. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009;101(4):673-83.
54. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 2010;5(8): e12445.
55. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J. 2011;30(4):756-69.
56. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138(3):592-603.
57. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761-72.
58. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 2010;126(11):2575-83.
59. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelial- mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011;71(9):3400-9.
60. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR- 200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009;4(9):e7181.
61. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià- Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011;17(9):1101-8.
62. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2011 Jun 1 [cited 2011 Dec 12];Available from: http:// www.ncbi.nlm.nih.gov/pubmed/21633010.
63. Hui ABY, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 2009;89 (5):597-606.
64. Bockmeyer CL, Christgen M, Müller M, Fischer S, Ahrens P, Länger F, et al. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat. 2011;130 (3):735-45.
65. Baffa R, Fassan M, Volinia S, O'Hara B, Liu C-G, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009;219(2):214-21.
66. Gill JG, Langer EM, Lindsley RC, Cai M, Murphy TL, Kyba M, et al. Snail and the microRNA-200 family act in opposition to regulate epithelial-to- mesenchymal transition and germ layer fate restriction in differentiating ESCs. Stem Cells. 2011;29(5):764-76.
67. Lin C-H, Jackson AL, Guo J, Linsley PS, Eisenman RN. Mycregulated microRNAs attenuate embryonic stem cell differentiation. EMBO J. 2009;28(20):3157-70.
68. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009;23(18):2140-51.
69. Gregory PA, Bracken CP, Smith E, Bert AG,Wright JA, Roslan S, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22(10):1686-98.
70. Neveu P, Kye MJ, Qi S, Buchholz DE, Clegg DO, Sahin M, et al. MicroRNA profiling reveals two distinct p53-relatedhuman pluripotent stem cell states. Cell Stem Cell. 2010;7 (6):671-81.
71. Samavarchi-Tehrani P, Golipour A, David L, Sung H-K, Beyer TA, Datti A, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell. 2010;7(1):64-77.
72. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG,Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68(19):7846-54.
73. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582-9. (Pubitemid 351772923)
74. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 2011;286(29):25992- 6002.
75. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283(22):14910-4.
76. Slabáková E, Pernicová Z, Slavíč ková E, Staršíchová A, Kozubík A, Souček K. TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/ Slug. Prostate. 2011;71(12):1332-43.
77. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene [Internet]. 2011 Aug 29 [cited 2011 Dec 13];Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 21874049.
78. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One. 2010;5 (1):e8697.
79. Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR- 200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128(6):1327-34.
80. Yuan J-H, Yang F, Chen B-F, Lu Z, Huo X-S, Zhou W-P, et al. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology. 2011;54(6):2025-35.
81. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim H-RC, et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009;27(8):1712-21.
82. Li Y, VandenBoom 2nd TG, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69(16):6704-12.
83. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, et al. EMT and stem cell-like properties associated with miR- 205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011;71(8):3087-97.
84. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al. Antitumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One. 2011;6(3):e17850.
85. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal. 2009;2(92):ra62.
86. Chang C-J, Chao C-H, Xia W, Yang J-Y, Xiong Y, Li C-W, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011;13 (3):317-23.
87. KimT, Veronese A, Pichiorri F, Lee TJ, Jeon Y-J, Volinia S, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011;208(5):875-83.
88. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, et al. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Research [Internet]. 2011 Sep 14 [cited 2011 Dec 13]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 21917857.
89. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009;37 (14):4850-61.
90. Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Medical Oncology (Northwood, London, England) [Internet].2011 Apr 13 [cited 2011 Dec 13];Available from: http://www. ncbi.nlm.nih.gov/pubmed/21487968.
91. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res. 2011;9(7):824-33.
92. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25(5):387-92. (Pubitemid 47362758)
93. Chou C-K, Chen R-F, Chou F-F, Chang H-W, Chen Y-J, Lee Y-F, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 2010;20(5):489-94.
94. Sun K, Wang W, Zeng J-jie, Wu C-tang, Lei S-tong, Li Gxin. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin. 2011;32 (3):375-84.
95. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, et al. The promyelocytic leukemia zinc fingermicroRNA- 221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008;68 (8):2745-54. (Pubitemid 351556272)
96. Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010;85(5):331-9.
97. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009;124(9):2236-42.
98. Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A, et al. Analysis of miR-221 and p27 expression in human gliomas. Mol Med Report. 2009;2(4):651-6.
99. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triplenegative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011;10 (3):507-17.
100. Zhao J-J, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA- 221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008;283(45):31079-86.
101. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010;102(10):706-21.
102. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, et al. microRNA-associated progression pathways andpotential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 2011;71(17):5635-45.
103. Sun Y, Wu J, Wu S-hung, Thakur A, Bollig A, Huang Y, et al. Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat. 2009;118(1):185-96.
104. Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, et al. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat. 2011;130(1):331-9.
105. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.
106. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009;15(16):5073-81.
107. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res. Treat. [Internet]. 2011 May 7 [cited 2011 Dec 14];Available from: http://www.ncbi.nlm.nih. gov/pubmed/21553120.
108. Gai Z, Zhou G, Itoh S, Morimoto Y, Tanishima H, Hatamura I, et al. Trps1 functions downstream of Bmp7 in kidney development. J Am Soc Nephrol. 2009;20(11):2403-11.
109. Chen JQ, Litton J, Xiao L, Zhang H-Z, Warneke CL, Wu Y, et al. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer. 2010;1(1):21-33.
110. Shah MY, Calin GA. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 2011;3(8):56.
111. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282(32):23716-24. (Pubitemid 47311902)
112. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/ p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27(43):5651-61.
113. Medina R, Zaidi SK, Liu C-G, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008;68(8):2773-80.
114. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27(Kip1) tumor suppressor by miR- 221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26(15):3699-708.
115. 1 in hepatocellular carcinoma. Mol Biol Rep. 2011;38(5):3029-35.
116. Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfò L, Rossi C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood. 2010;115(19):3949-59.
117. MercatelliN, CoppolaV, Bonci D,Miele F, Costantini A, Guadagnoli M, et al. The inhibition of the highly expressed miR-221 and miR- 222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 2008;3(12):e4029.
118. Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P, et al. Cosuppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol. 2009;34(6):1653-60.
119. Park J-K, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, et al. miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. Cancer Res. 2011;71(24):7608-16.
120. Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila). 2011;4(1):76-86.
121. Janssen EAM, Øvestad IT, Skaland I, Søiland H, Gudlaugsson E, Kjellevold KH, et al. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cell Oncol. 2009;31(5):335-43.
122. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, et al. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 2003;63(14):4174-80. (Pubitemid 36917943)
123. Bao J-J, Le X-F, Wang R-Y, Yuan J, Wang L, Atkinson EN, et al. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspaseindependent calpain-dependent pathway. Cancer Res. 2002;62 (24):7264-72. (Pubitemid 36025248)
124. Park J-K, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009;38(7):e190-199.
125. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285 (28):21496-507.
126. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, et al. miR- 221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol. 2010;36(4):913-20.
127. Zhu L, Chow LWC, Loo WTY, Guan X-Y, Toi M. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res. 2004;10 (14):4639-44. (Pubitemid 38955513)
128. Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001;61 Suppl 2:73-82. (Pubitemid 33033428)
129. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008;283 (44):29897-903.
130. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, et al. Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic Signal. J Biol Chem. 2011;286(49):42292-302.
131. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30(9):1082-97.
132. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006;66 (24):11954-66. (Pubitemid 46094209)
133. Kalkhoven E, Kwakkenbos-Isbrücker L, Mummery CL, de Laat SW, van den Eijnden-van Raaij AJ, van der Saag PT, et al. The role of TGF-beta production in growth inhibition of breast-tumor cells by progestins. Int J Cancer. 1995;61(1):80-6.
134. Sovak MA, Arsura M, Zanieski G, Kavanagh KT, Sonenshein GE. The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation ofaberrant nuclear factor-kappaB/Rel expression. Cell Growth Differ. 1999;10(8):537-44. (Pubitemid 29399061)
135. Brioschi M, Fischer J, Cairoli R, Rossetti S, Pezzetti L, Nichelatti M, et al. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia. 2010;12(11):866-76.
136. Felicetti F, Bottero L, Felli N, Mattia G, Labbaye C, Alvino E, et al. Role of PLZF in melanoma progression. Oncogene. 2004;23 (26):4567-76. (Pubitemid 38850404)
137. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005;24(8):1434-44. (Pubitemid 40343123)
138. Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, et al. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene. 2010;29(5):662-73.
139. Ndlovu'Matladi N, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, Haegeman G, et al. Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol. 2009;29 (20):5488-504.
140. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, et al. A MicroRNA targeting dicer for metastasis control. Cell. 2010;141(7):1195-207.
141. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin Y-L, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010;467(7318):986-90.
142. Fontemaggi G, Gurtner A, Damalas A, Costanzo A, Higashi Y, Sacchi A, et al. deltaEF1 repressor controls selectively p53 family members during differentiation. Oncogene. 2005;24(49):7273-80. (Pubitemid 41622231)